Cargando…

Pharmacokinetics and Target Attainment of Ceftobiprole in Asian and Non‐Asian Subjects

Ceftobiprole is a broad‐spectrum cephalosporin. The objective of this study was to test the hypothesis that the pharmacokinetics (PK) and exposure of ceftobiprole in Asian subjects are similar to those in non‐Asian subjects. Three approaches were followed. The first compared the individual PK estima...

Descripción completa

Detalles Bibliográficos
Autores principales:	Muller, A. E., Punt, N., Engelhardt, M., Schmitt‐Hoffmann, A. H., Mouton, J. W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2018
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6618770/ https://www.ncbi.nlm.nih.gov/pubmed/29768717 http://dx.doi.org/10.1002/cpdd.465

Ejemplares similares

2531. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Ceftobiprole Dosing Regimens for Patients with Staphylococcus aureus Bacteremia (SAB)
por: Bhavnani, Sujata M, et al.
Publicado: (2023)

Ceftobiprole: pharmacokinetics and PK/PD profile
por: Azanza Perea, José Ramón, et al.
Publicado: (2019)

Pharmacokinetics and Safety of Ceftobiprole in Pediatric Patients
por: Rubino, Christopher M., et al.
Publicado: (2021)

Pharmacokinetics and Dosing of Ceftobiprole Medocaril for the Treatment of Hospital- and Community-Acquired Pneumonia in Different Patient Populations
por: Torres, Antonio, et al.
Publicado: (2016)

2530. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Ceftobiprole Dose Selection for the Treatment of Patients with Acute Bacterial Skin and Skin Structure Infections (ABSSSI) and Community-Acquired Bacterial Pneumonia (CABP)
por: Bhavnani, Sujata M, et al.
Publicado: (2023)

Effect of rifampin and itraconazole on the pharmacokinetics of zanubrutinib (a Bruton's tyrosine kinase inhibitor) in Asian and non-Asian healthy subjects
por: Mu, Song, et al.
Publicado: (2019)

2561. Population Pharmacokinetic Analyses for Ceftobiprole Using Data from Phase 1 and 3 Studies
por: Cammarata, Anthony P, et al.
Publicado: (2023)

Ceftobiprole medocaril
por: Méndez, Raúl, et al.
Publicado: (2022)

A Systematic Review on Antimicrobial Pharmacokinetic Differences between Asian and Non-Asian Adult Populations
por: Setiawan, Eko, et al.
Publicado: (2023)

Safety and tolerability of ceftobiprole
por: Grau, Santiago
Publicado: (2019)

Ceftobiprole for the treatment of pneumonia
por: Cillóniz, Catia, et al.
Publicado: (2019)

Population pharmacokinetics of vedolizumab in Asian and non-Asian patients with ulcerative colitis and Crohn’s disease
por: Okamoto, Hiroyuki, et al.
Publicado: (2021)

Pharmacokinetics, pharmacodynamics, and safety of verinurad with and without allopurinol in healthy Asian, Chinese, and non‐Asian participants
por: Johansson, Susanne, et al.
Publicado: (2022)

2532. Pharmacokinetic-Pharmacodynamic Analyses for Ceftobiprole Efficacy Based on Phase 3 Data from Patients with Staphylococcus aureus Bacteremia
por: Bhavnani, Sujata M, et al.
Publicado: (2023)

Target attainment and population pharmacokinetics of flucloxacillin in critically ill patients: a multicenter study
por: Meenks, Sjoerd D., et al.
Publicado: (2023)

Possible clinical indications of ceftobiprole
por: Barberán, José
Publicado: (2019)

Ceftobiprole: a clinical view
por: Pérez-Crespo, Pedro María Martínez, et al.
Publicado: (2021)

Pharmacokinetics, pharmacodynamics, and safety of single- and multiple-dose intravenous ceftobiprole in healthy Chinese participants
por: Li, Wan-Zhen, et al.
Publicado: (2021)

Ethnicity evaluation of ferric pyrophosphate citrate among Asian and Non-Asian populations: a population pharmacokinetics analysis
por: Zhang, Lingxiao, et al.
Publicado: (2022)

Educational Attainment and Prevalence of Cardiovascular Health (Life’s Simple 7) in Asian Americans
por: Alam, Md Towfiqul, et al.
Publicado: (2021)

Pharmacokinetics and pharmacodynamics of intravenous and inhaled fluticasone furoate in healthy Caucasian and East Asian subjects
por: Allen, Ann, et al.
Publicado: (2014)

Mechanisms of action and antimicrobial activity of ceftobiprole
por: Morosini, María-Isabel, et al.
Publicado: (2019)

Population Pharmacokinetic and Pharmacokinetic/Pharmacodynamic Target Attainment Analyses for Dalbavancin in Pediatric Patients
por: Carrothers, Timothy J., et al.
Publicado: (2022)

739. Prediction of Cefiderocol Pharmacokinetics and Probability of Target Attainment in Pediatric Subjects for Proposing Dose Regimens
por: Katsube, Takayuki, et al.
Publicado: (2019)

Pharmacokinetics, pharmacodynamics, and tolerability of verinurad, a selective uric acid reabsorption inhibitor, in healthy Japanese and non-Asian male subjects
por: Hall, Jesse, et al.
Publicado: (2018)

Population pharmacokinetics and target attainment of ciprofloxacin in critically ill patients
por: Abdulla, Alan, et al.
Publicado: (2020)

Ceftobiprole for the treatment of pneumonia: a European perspective
por: Liapikou, Adamantia, et al.
Publicado: (2015)

Ceftobiprole Perspective: Current and Potential Future Indications
por: Lupia, Tommaso, et al.
Publicado: (2021)

Population Pharmacokinetic Model and Pharmacokinetic Target Attainment of Micafungin in Intensive Care Unit Patients
por: Martial, Lisa C., et al.
Publicado: (2017)

The Pharmacokinetics and Target Attainment of Antimicrobial Drugs Throughout Pregnancy: Part III Non-penicillin and Non-cephalosporin Drugs
por: Groen, F., et al.
Publicado: (2023)

Dalbavancin Population Pharmacokinetic Modeling and Target Attainment Analysis
por: Carrothers, Timothy J., et al.
Publicado: (2019)

Meropenem Pharmacokinetics and Target Attainment in Critically Ill Patients
por: Gan, Yuhong, et al.
Publicado: (2023)

Early improvement in severely ill patients with pneumonia treated with ceftobiprole: a retrospective analysis of two major trials
por: Scheeren, Thomas W. L., et al.
Publicado: (2019)

Genetic and Pharmacokinetic Determinants of Response to Transdermal Nicotine in White, Black and Asian Non-Smokers
por: Dempsey, Delia A., et al.
Publicado: (2013)

Pharmacokinetics and pharmacogenetics of the MEK1/2 inhibitor, selumetinib, in Asian and Western healthy subjects: a pooled analysis
por: Dymond, Angela W., et al.
Publicado: (2017)

Signatures of tumour immunity distinguish Asian and non-Asian gastric adenocarcinomas
por: Lin, Suling J, et al.
Publicado: (2015)

Pharmacokinetics and Target Attainment of Antimicrobial Drugs Throughout Pregnancy: Part I—Penicillins
por: Hesse, M. R., et al.
Publicado: (2023)

Pharmacokinetics of Risankizumab in Asian Healthy Subjects and Patients With Moderate to Severe Plaque Psoriasis, Generalized Pustular Psoriasis, and Erythrodermic Psoriasis
por: Khatri, Amit, et al.
Publicado: (2019)

Pharmacokinetic Variability and Target Attainment of Fluconazole in Critically Ill Patients
por: Van Daele, Ruth, et al.
Publicado: (2021)

Anti-VEGF therapy in mRCC: differences between Asian and non-Asian patients
por: Wang, Y, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_aojn6budscj7ampv34etgqtudj